Small-Molecule Targets in Tumor Immunotherapy

doi:10.1007/s13659-018-0177-7

应用天然产物 ›› 2018, Vol. 8 ›› Issue (4): 297-301.DOI: 10.1007/s13659-018-0177-7

Small-Molecule Targets in Tumor Immunotherapy

Hui-Fang Zhu^1,2, Yan Li¹

1 State Key Laboratory of Phytochemistry and Plant Resources in West China, Kunming Institute of Botany, Chinese Academy of Sciences, 132#Lanhei Road, Kunming 650201, Yunnan, People's Republic of China;
2 University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China

收稿日期:2018-05-02 修回日期:2018-07-02 出版日期:2018-08-24 发布日期:2018-08-28
通讯作者: Yan Li,liyanb@mail.kib.ac.cn
基金资助:
This work was supported financially by the funding of Exploitation and Utilization of Abundant Natural Products from Plants from Kunming Institute of Botany (KIB2017009), the National Natural Science Foundation of China (U1402227), the 100 Talents Program of the Chinese Academy of Sciences (Y. Li), the Program of Recruited Top Talent of Sciences and Technology of Yunnan Province (2009CI120) and the Independent Program of Key Laboratory of Natural Pharmaceutical Chemistry of Yunnan Province (Y. Li).

Small-Molecule Targets in Tumor Immunotherapy

Hui-Fang Zhu^1,2, Yan Li¹

1 State Key Laboratory of Phytochemistry and Plant Resources in West China, Kunming Institute of Botany, Chinese Academy of Sciences, 132#Lanhei Road, Kunming 650201, Yunnan, People's Republic of China;
2 University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China

Received:2018-05-02 Revised:2018-07-02 Online:2018-08-24 Published:2018-08-28
Contact: Yan Li,liyanb@mail.kib.ac.cn
Supported by:
This work was supported financially by the funding of Exploitation and Utilization of Abundant Natural Products from Plants from Kunming Institute of Botany (KIB2017009), the National Natural Science Foundation of China (U1402227), the 100 Talents Program of the Chinese Academy of Sciences (Y. Li), the Program of Recruited Top Talent of Sciences and Technology of Yunnan Province (2009CI120) and the Independent Program of Key Laboratory of Natural Pharmaceutical Chemistry of Yunnan Province (Y. Li).

摘要/Abstract

摘要： Cancer immunotherapy has been widely recognized as a powerful approach to fight cancers. To date, over 50 phase III trials in cancer immunotherapy are in progress. Among the many immunotherapy approaches, immune checkpoint therapy has attracted considerable attention. The reported clinical success of targeting the T cell immune checkpoint receptors PD-1 or CTLA4 by antibodies blockade in advanced stages of cancers has demonstrated the importance of immune modulation. But antibodies-based immunotherapy confronted with some disadvantages, such as immunogenicity, stability, membrane permeability, and production cost. Therefore, alternative approaches including small-molecule-regulated immune response are being introduced. In this review, we focused on some of the key intracellular pathways where smallmolecule therapeutic is potential and attractive, which highlights the great potential of natural products in this field.

关键词: Cancer immunotherapy, IDO1, PD(L)-1, NKG2DL, STING, TLRs

Abstract: Cancer immunotherapy has been widely recognized as a powerful approach to fight cancers. To date, over 50 phase III trials in cancer immunotherapy are in progress. Among the many immunotherapy approaches, immune checkpoint therapy has attracted considerable attention. The reported clinical success of targeting the T cell immune checkpoint receptors PD-1 or CTLA4 by antibodies blockade in advanced stages of cancers has demonstrated the importance of immune modulation. But antibodies-based immunotherapy confronted with some disadvantages, such as immunogenicity, stability, membrane permeability, and production cost. Therefore, alternative approaches including small-molecule-regulated immune response are being introduced. In this review, we focused on some of the key intracellular pathways where smallmolecule therapeutic is potential and attractive, which highlights the great potential of natural products in this field.

Key words: Cancer immunotherapy, IDO1, PD(L)-1, NKG2DL, STING, TLRs

Hui-Fang Zhu, Yan Li. Small-Molecule Targets in Tumor Immunotherapy[J]. 应用天然产物, 2018, 8(4): 297-301.

Hui-Fang Zhu, Yan Li. Small-Molecule Targets in Tumor Immunotherapy[J]. Natural Products and Bioprospecting, 2018, 8(4): 297-301.

参考文献

1. P. Letendre, V. Monga, M. Milhem, Y. Zakharia, Future Oncol. 13, 625-636 (2017)
2. J.D. Wolchok, F.S. Hodi, J.S. Weber, J.P. Allison, W.J. Urba, C. Robert, S.J. O'Day, A. Hoos, R. Humphrey, D.M. Berman, N. Lonberg, A.J. Korman, Ann. N. Y. Acad. Sci. 1291, 1-13 (2013)
3. S.J. Antonia, A. Villegas, D. Daniel, D. Vicente, S. Murakami, R. Hui, T. Yokoi, A. Chiappori, K.H. Lee, M. de Wit, B.C. Cho, M. Bourhaba, X. Quantin, T. Tokito, T. Mekhail, D. Planchard, Y.C. Kim, C.S. Karapetis, S. Hiret, G. Ostoros, K. Kubota, J.E. Gray, L. Paz-Ares, J. de Castro Carpeno, C. Wadsworth, G. Melillo, H. Jiang, Y. Huang, P.A. Dennis, M. Ozguroglu, P. Investigators, N. Engl. J. Med. 377, 1919-1929 (2017)
4. M.D. Copur, D. Gauchan, R. Ramaekers, N. Engl. J. Med. 378, 868 (2018)
5. D. Meininger, L. Zalameda, Y. Liu, L.P. Stepan, L. Borges, J.D. McCarter, C.L. Sutherland, Biochim. Biophys. Acta 1814, 1947-1954 (2011)
6. E. Vacchelli, F. Aranda, A. Eggermont, C. Sautes-Fridman, E. Tartour, E.P. Kennedy, M. Platten, L. Zitvogel, G. Kroemer, L. Galluzzi, Oncoimmunology 3, e957994 (2014)
7. C. Sheridan, Nat. Biotechnol. 33, 321-322 (2015)
8. D.A. Wainwright, M. Dey, A. Chang, M.S. Lesniak, Front. Immunol. 4, 116 (2013)
9. G.C. Prendergast, R. Metz, A.J. Muller, Cell Cycle 8, 1818-1819 (2009)
10. S.L. Topalian, C.G. Drake, D.M. Pardoll, Cancer Cell 27, 450-461 (2015)
11. A.D. Bardoli, M. Afshar, R. Viney, M. Foster, E. Porfiri, A. Zarkar, R. Stevenson, N.D. James, R.T. Bryan, P. Patel, Future Oncol. 12, 595-600 (2016)
12. P. Khanna, N. Blais, P.O. Gaudreau, L. Corrales-Rodriguez, Clin. Lung Cancer 18, 13-22 (2017)
13. R.J. Sullivan, K.T. Flaherty, Nat. Rev. Clin. Oncol. 12, 625-626 (2015)
14. R.J. Motzer, N.M. Tannir, D.F. McDermott, O. Aren Frontera, B. Melichar, T.K. Choueiri, E.R. Plimack, P. Barthelemy, C. Porta, S. George, T. Powles, F. Donskov, V. Neiman, C.K. Kollmannsberger, P. Salman, H. Gurney, R. Hawkins, A. Ravaud, M.O. Grimm, S. Bracarda, C.H. Barrios, Y. Tomita, D. Castellano, B.I. Rini, A.C. Chen, S. Mekan, M.B. McHenry, M. WindRotolo, J. Doan, P. Sharma, H.J. Hammers, B. Escudier, I. CheckMate, N. Engl. J. Med. 378, 1277-1290 (2018)
15. D.S. Bae, Y.K. Hwang, J.K. Lee, Cell. Immunol. 276, 122-127 (2012)
16. N. Nausch, A. Cerwenka, Oncogene 27, 5944-5958 (2008)
17. P. Nowbakht, M.C. Ionescu, A. Rohner, C.P. Kalberer, E. Rossy, L. Mori, D. Cosman, G. De Libero, A. Wodnar-Filipowicz, Blood 105, 3615-3622 (2005)
18. J. Shen, J. Pan, C. Du, W. Si, M. Yao, L. Xu, H. Zheng, M. Xu, D. Chen, S. Wang, P. Fu, W. Fan, Cell Death Dis. 8, e2740 (2017)
19. X. Wu, Y. Tao, J. Hou, X. Meng, J. Shi, Neoplasia 14, 1178-1189 (2012)
20. S. Shin, M. Kim, S.J. Lee, K.S. Park, C.H. Lee, Cancer Genomics Proteomics 14, 349-362 (2017)
21. S. Kiany, G. Huang, E.S. Kleinerman, Oncoimmunology 6, e1333214 (2017)
22. J.E. Butler, M.B. Moore, S.R. Presnell, H.W. Chan, N.J. Chalupny, C.T. Lutz, J. Immunol. 182, 6600-6609 (2009)
23. L. Shi, H. Lin, G. Li, Y. Sun, J. Shen, J. Xu, C. Lin, S. Yeh, X. Cai, C. Chang, Cancer Lett. 373, 45-56 (2016)
24. X. Lu, Z. Zhu, L. Jiang, X. Sun, Z. Jia, S. Qian, J. Li, L. Ma, Am. J. Transl. Res. 7, 1838-1849 (2015)
25. L. Ma, Z. Zhu, X. Lu, L. Jiang, M. Zhou, S. Qian, J. Li, Zhonghua Xue Ye Xue Za Zhi 35, 438-442 (2014)
26. S.R. Woo, L. Corrales, T.F. Gajewski, Trends Immunol. 36, 250-256 (2015)
27. L. Corrales, S.M. McWhirter, T.W. Dubensky Jr., T.F. Gajewski, J. Clin. Invest. 126, 2404-2411 (2016)
28. P. Nakhaei, J. Hiscott, R. Lin, J. Mol. Cell. Biol. 2, 110-112 (2010)
29. H. Ishikawa, G.N. Barber, Cell. Mol. Life Sci. 68, 1157-1165 (2011)
30. L. Corrales, S.R. Woo, J.B. Williams, S.M. McWhirter, T.W. Dubensky Jr., T.F. Gajewski, J. Immunol. 196, 3191-3198 (2016)
31. J. Wang, P. Li, M.X. Wu, J. Invest. Dermatol. 136, 2183-2191 (2016)
32. A. Sanchez Alberti, A.E. Bivona, N. Cerny, K. Schulze, S. Weissmann, T. Ebensen, C. Morales, A.M. Padilla, S.I. Cazorla, R.L. Tarleton, C.A. Guzman, E.L. Malchiodi, NPJ Vaccines 2, 9 (2017)
33. J.M. Weiss, M.V. Guerin, F. Regnier, G. Renault, I. Galy-Fauroux, L. Vimeux, V. Feuillet, E. Peranzoni, M. Thoreau, A. Trautmann, N. Bercovici, Oncoimmunology 6, e1346765 (2017)
34. E.J. Hennessy, A.E. Parker, L.A. O'Neill, Nat. Rev. Drug. Discov. 9, 293-307 (2010)
35. A.J. Smith, Y. Li, H.G. Bazin, J.R. St-Jean, D. Larocque, J.T. Evans, J.R. Baldridge, Vaccine 34, 4304-4312 (2016)
36. A.I. Rubin, E.H. Chen, D. Ratner, N. Engl. J. Med. 353, 2262-2269 (2005)
37. C. Guiducci, A.P. Vicari, S. Sangaletti, G. Trinchieri, M.P. Colombo, Cancer Res. 65, 3437-3446 (2005)

Small-Molecule Targets in Tumor Immunotherapy

Small-Molecule Targets in Tumor Immunotherapy

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 0

编辑推荐

Metrics

本文评价